ArticleJapanese journal of ophthalmology2026
Safety outcomes of half-dose fluorescein and indocyanine green angiography: a clinical assessment of adverse events.
Article in Japanese journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate whether half‑dose administration of fluorescein and indocyanine green is associated with the incidence of adverse events during fluorescein angiography (FA) and indocyanine green angiography (ICGA). STUDY
designRetrospective cohort study.
methodsWe analyzed 10,435 angiographic examinations in 10,435 unique patients performed using standard doses (fluorescein, 5 mL [500 mg]; indocyanine green, 2 mL [25 mg]) between April 2015 and March 2023, and half doses (fluorescein, 2.5 mL [250 mg]; indocyanine green, 1 mL [12.5 mg]) between April 2023 and March 2024. Explanatory variables included dye dose (half vs. standard), age, sex, diabetes, hypertension, asthma, history of drug allergy, vital signs at examination (systolic/diastolic blood pressure, pulse rate), and meteorological factors (temperature, atmospheric pressure). After univariable analyses, multivariable logistic regression was performed. P < 0.05 was considered statistically significant.
resultsAdverse events assessed in the main analyses included rash, nausea/vomiting during FA, ICGA, or combined FA+ICGA, and hypotension. The overall incidence of adverse events was significantly lower in the half‑dose group (6.21%) than in the standard‑dose group (10.65%; P < 0.001). Half-dose administration was associated with lower odds of rash (odds ratio [OR] = 0.46; P = 0.001), nausea/vomiting during FA (OR = 0.24; P < 0.001), and nausea/vomiting during combined FA+ICGA (OR = 0.58; P = 0.002). Younger age was an independent risk factor for several adverse events.
conclusionsHalf‑dose dye administration was associated with lower incidences of rash and nausea/vomiting. Dose reduction may contribute to improved safety in FA and ICGA.
Indexed as
Identifiers
42828611What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.